BioNB announces new executive director, launches subsidiary

This year has been an exciting one for BioNB with the launch of a new start-up company under BioNB’s banner and a growing need to scale up that new entity, called 1812 Hemp. As a result, BioNB’s executive director, Meaghan Seagrave has moved over to lead the new subsidiary company and Jennifer O’Donnell has assumed the role of executive director of BioNB as of  June 3, 2019.

Jennifer joined BioNB in 2013 following her work in several early-stage biotech companies where she was involved with diagnostic testing for the agriculture industry, high-throughput genomics, and crop biotechnology. She holds an M.Sc. in biochemistry and molecular biology from Dalhousie University.

Jennifer has been responsible for delivering commercialization support services and bioscience sector expertise to many of BioNB’s clients over the years. Recently, she co-authored Canada’s National Bioeconomy Strategy, helped to lead a Canadian Supercluster application, participated in regional and national scientific funding review committees, and works across industries and borders to build collaborations and identify opportunities that support stakeholders in New Brunswick.

The BioNB team would like to also acknowledge Meaghan’s impressive contributions to the province and the sector which are too numerous to mention here. We are overjoyed that our paths will continue to be intertwined as BioNB and its affiliates reach for even greater heights moving forward.

Read an overview of BioNB’s history and Meaghan’s role in it: BioNB Our History.